262 related articles for article (PubMed ID: 35830649)
21. Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.
Raymakers AJN; Costa S; Cameron D; Regier DA
BMC Cancer; 2020 Oct; 20(1):992. PubMed ID: 33050897
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.
Abramson JS; Bengston E; Redd R; Barnes JA; Takvorian T; Sokol L; Lansigan F; Armand P; Shah B; Jacobsen E; Martignetti R; Turba E; Metzler S; Patterson V; LaCasce AS; Bello CM
Blood Adv; 2023 Apr; 7(7):1130-1136. PubMed ID: 36053786
[TBL] [Abstract][Full Text] [Related]
24. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.
Connors JM; Ansell SM; Fanale M; Park SI; Younes A
Blood; 2017 Sep; 130(11):1375-1377. PubMed ID: 28733323
[No Abstract] [Full Text] [Related]
25. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.
Winter A; Liu N; Surinach A; Fanale M; Yu KS; Narkhede M
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):527-534. PubMed ID: 37121857
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
27. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
28. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
29. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
Radford J; Illidge T; Counsell N; Hancock B; Pettengell R; Johnson P; Wimperis J; Culligan D; Popova B; Smith P; McMillan A; Brownell A; Kruger A; Lister A; Hoskin P; O'Doherty M; Barrington S
N Engl J Med; 2015 Apr; 372(17):1598-607. PubMed ID: 25901426
[TBL] [Abstract][Full Text] [Related]
30. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ; Lowry L; Horwich A; Jack A; Mead B; Hancock BW; Smith P; Qian W; Patrick P; Popova B; Pettitt A; Cunningham D; Pettengell R; Sweetenham J; Linch D; Johnson PW
J Clin Oncol; 2009 Nov; 27(32):5390-6. PubMed ID: 19738111
[TBL] [Abstract][Full Text] [Related]
31. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
[TBL] [Abstract][Full Text] [Related]
32. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
Zinzani PL; Magagnoli M; Frezza G; Barbieri E; Gherlinzoni F; Galuppi A; Bendandi M; Merla E; Albertini P; Babini L; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):553-9. PubMed ID: 10048428
[TBL] [Abstract][Full Text] [Related]
33. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
35. Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
Phillips T; Liu N; Bloudek B; Migliaccio-Walle K; Reynolds J; Burke JM
J Manag Care Spec Pharm; 2023 Dec; 29(12):1312-1320. PubMed ID: 37921077
[TBL] [Abstract][Full Text] [Related]
36. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
Evens AM; Advani RH; Helenowski IB; Fanale M; Smith SM; Jovanovic BD; Bociek GR; Klein AK; Winter JN; Gordon LI; Hamlin PA
J Clin Oncol; 2018 Oct; 36(30):3015-3022. PubMed ID: 30179569
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
Kumar A; Casulo C; Advani RH; Budde E; Barr PM; Batlevi CL; Caron P; Constine LS; Dandapani SV; Drill E; Drullinsky P; Friedberg JW; Grieve C; Hamilton A; Hamlin PA; Hoppe RT; Horwitz SM; Joseph A; Khan N; Laraque L; Matasar MJ; Moskowitz AJ; Noy A; Palomba ML; Schöder H; Straus DJ; Vemuri S; Yang J; Younes A; Zelenetz AD; Yahalom J; Moskowitz CH
J Clin Oncol; 2021 Jul; 39(20):2257-2265. PubMed ID: 33909449
[TBL] [Abstract][Full Text] [Related]
38. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial.
Phillips T; Migliaccio-Walle K; Yu KS; Bloudek B; Liu N; Fanale M; Burke JM
Leuk Lymphoma; 2023 May; 64(5):1017-1025. PubMed ID: 37074674
[TBL] [Abstract][Full Text] [Related]
39. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study.
Rueda Domínguez A; Márquez A; Gumá J; Llanos M; Herrero J; de Las Nieves MA; Miramón J; Alba E
Ann Oncol; 2004 Dec; 15(12):1798-804. PubMed ID: 15550585
[TBL] [Abstract][Full Text] [Related]
40. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
Johnson PW; Radford JA; Cullen MH; Sydes MR; Walewski J; Jack AS; MacLennan KA; Stenning SP; Clawson S; Smith P; Ryder D; Hancock BW;
J Clin Oncol; 2005 Dec; 23(36):9208-18. PubMed ID: 16314615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]